anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject new derivative consisting of a specific adenine-1- N-oxide derivative having a function of preventing an inflammatory cell from attaching to a target organ cell, useful, e.g. as a medicine for immunological diseases, such as autoimmune, allergic and inflammatory diseases. SOLUTION: This new adenine-1-N-oxide derivative is shown by formula I (R1 is H or a 1-4C alkyl; R2 is H, a 1-4C alkyl or a 1-4C alkoxy; R3 is a (substituted)phenyl or naphthyl, which is not substituted or substituted with 1 to 3 groups, such as a 1-4C alkyl, a 1-4C alkoxy, trifluoromehyl, nitro, phenyl, a halogeno or the like), e.g. 9-(4-chlorobenzyl)adenine-1-N-oxide, and useful as a medicine or the like for immunological diseases in which an inflammatory cell is involved, e.g. autoimmune and allergic diseases. The compound is obtained by reacting a substituted adenine derivative shown by formula II with an arylmethyl halide shown by the formula R3 -CH2 -X (X is Cl, Br or I) in the presence of a base.
Surgical dressing material comprises comminuted egg-shell membrane the total surface area of which is greater than that of the weight of egg-shell membrane.  Egg-shell membranes are separated from cooked or uncooked egg-shells mechanically or chemically and are disintegrated in a homogenizer or blender in air or a non-softening liquid to form non-fibrous particles or in a softening liquid or gas to form fibres having a diameter of the order of 4-7 microns.  Softening liquids used are water-free methyl ethyl ketone, 1 : 4-dioxane, benthiazol, pyridine, pentane-diane or chloroform.  Softening agents are water, steam, aqueous solutions, methyl alcohol, glacial acetic acid, mercapto-acetic acid, molten phenol crystals, formamide, propionic acid, beta-mercapto-propionic acid, lactic acid, anhydrous pyridine, chlorophenols or cresols.  The membrane fibres or particles are separated from the suspending liquid by filtration, centrifuging, evaporation &c. which is repeated after washing. Any aggregates of fibres or particles so formed are separated in a homogenizer, there being no suspending liquid.  The resulting powder or fibrous mass is applied to the wound directly or to a paper, fabric or synthetic plastic backing to which it is made to adhere by compositions including pectin, gelatin, starch or starch derivatives, vegetable gums or synthetic resinous polyamine substances.  Fibrous membrane particles may be felted together with a proportion of natural or synthetic fibres or during the felting operation a layer of natural or synthetic fibres may be deposited on a layer of egg-shell membrane fibres.  The fibres or powder may be partially digested with ensymes, e.g. papain, ficin, pepsin, trypsin, bromelin &c. or reduced or oxidized by hydrogen peroxide, urea peroxide, peracetic acid, performic acid mercapto-acetic acid, mercapto-propionic acid or substances with a thiol group and their soluble salts.  The fibre or powder may be sterilized or combined with drugs, antibiotics or bacteriostatic agents, e.g. neomycin, bacitracin, tetracyclines, chloramphericol or "sulfa" drugs.
The invention, in part, relates to skin care or hair care compositions containing a source of carbon dioxide. The carbon dioxide is conveniently entrained in a gel-network, or liquid crystalline phase, immediately prior to skin or hair application. A substantial portion of the carbon dioxide will be lost from the product upon application to the skin or hair. However, a sufficient amount of carbon dioxide will remain in the product to stimulate oxygen flow to the outer layers of the skin with the apparent retardation of skin aging. The present invention also relates to the field of hair treatment and particularly to the removal of chemically bound residues and mineral deposits from hair. Hair may act as a sink for environmental minerals and heavy metals. In addition to undesirable changes in color and appearance, environmental minerals may have an adverse effect on chemical hair treatments. Mineral deposits in tap water may strip away highlights, darkening hair to a brassier hue. In both skin and hair care products, the liberated carbon dioxide also functions to facilitate the delivery of active or functional substances to keratinous substrates, such as skin and hair.
Pediatric vehicular hyperthermia (PVH) has aroused wide public concern recently. High temperatures in closed vehicles with full sun exposure and no ventilation in summer seriously endanger children's lives. Aiming at this practical problem, this study first took the temperature of child's core body as a standard, and divided the hyperthermia into three stages: un-compensable heating (Tc > 37ºC), heat stroke (Tc > 40ºC) and critical thermal maximum (Tc > 42ºC). On this basis, two weeks of outdoor parking experiments during 10:00-18:00, using an equivalent size dummy were conducted to explore the influence of ambient temperature and solar irradiation on cabin temperature, humidity, and child's core body temperature. According to the experimental results, at an ambient temperature of 32.4ºC, the child in the cabin developed un-compensable heating within 72 min, suffered heat stroke within 129 min, and reached the critical thermal maximum within 151 min. Considering the limitations of the experiment, a numerical study was conducted to analyze the effects of ambient temperature, solar irradiation, and window radiation characteristics on cabin temperature and flow fields comprehensively. Simulation results were in good agreement with the experiments: even at low ambient temperature Ta = 23ºC or weak solar irradiation (ts = 18:00) condition, the temperature in a closed compartment could reach the "hazardous" level. This study can provide guidance for public to increase security and prevention awareness, and promote the development of relevant policies and technologies.
Participants receive a single, peripheral intravenous (IV) infusion of UX053. After completion of the 90-day Follow up Period, participants can enter the open label repeat dose (OL-RD) cohort where they will receive UX053 every 4 weeks (Q4W) for 4 doses. Participants will also receive premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
Ankle foot orthoses (AFOs) are medical devices often used to support the foot and ankle during daily activities. Carbon fiber custom dynamic orthoses (CDOs), one subset of AFOs, that consist of a proximal cuff that wraps around the leg just below the knee, a posterior carbon fiber strut that runs the length of the leg and bends to store and return energy during gait, a semi-rigid carbon fiber footplate that acts as a lever arm to bend the posterior strut, and in some cases a foam heel wedge placed between the footplate and the shoe. Different CDO design characteristics, such as posterior strut stiffness, device alignment, and heel cushion height and stiffness have been studied in the past. While different design characteristics have been studied previously, there is little information available concerning the proximal cuff and how it impacts patient outcomes. Different types of AFOs and CDOs have been used in an effort to offload the limb for years. Both CDOs and patellar tendon bearing (PTB) style AFOs have been shown to reduce forces acting on the plantar surface of the foot. While multiple studies have indicated the importance of fastening the proximal cuff, few have actually investigated the forces acting within the proximal cuff. A loose proximal cuff has been associated with pistoning of the limb, where the limb translates down within the proximal cuff during loading, potentially increasing forces acting on the foot and reducing the offloading effects of the orthosis. Only one study investigated the effects of altering forces within the proximal cuff by adding more padding to the proximal cuff, which was shown to improve limb offloading.

A better understanding of the forces acting within the proximal cuff, and how these effect patient outcomes would help to guide future AFO related research studies, provision, and patient education. At this point in time there is little guidance available to inform patients how tightly they need to secure the proximal cuff when wearing an AFO, many clinicians recommend tightening it so that it's secure, but not uncomfortable. The ability to measure forces within the proximal cuff and an idea of the range of forces seen in a clinical setting will act as a first step to better understanding how forces acting within the proximal cuff impact patient outcomes.
PURPOSE: To obtain a new allergen to pollen of Chamaecyraris obtusa having a specific amino acid sequence as a T-cell epitope and a B-cell epitope and useful for diagnosis, prevention or curing, etc., of an antigen-specific pollinosis of Chamaecyraris obtusa. CONSTITUTION: This novel allergen to pollen of Chamaecyraris obtusa is composed of an allergen to pollen of Chamaecyraris obtusa Cha. o. I having an amino acid sequence expressed by formula I and an allergen to pollen of Chamaecyraris obtusa Cha. o. II having an amino acid sequence expressed by formula II. This allergen is useful for diagnosis, prevention or curing of an antigen-specific pollinosis of Chamaecyraris obtusa. This allergen to pollen of Chamaecyraris obtusa is obtained by extracting mRNA from pollen of Chamaecyraris obtusa in an usual method, synthesizing cDNA using the extract as a mold, producing a cDNA library, screening the library using a probe, integrating the resultant DNA of allergen to pollen of Chamaecyraris obtusa into a vector and manifesting in a host cell.
A medical therapy device may include a user interface (6100) such as a combined touchscreen/dial user interface, for input of operation parameters. The user interface may include a dial and a touchscreen to display a subset of a list of items. Each item may represent a parameter of the medical device. The displayed subset may include a pre-selected item that may provide a pre-selection indication for a particular item. Rotation of the dial may move the pre-selection indication so it may change between items on the displayed subset. In response to a swipe gesture on the touchscreen, the displayed subset may scroll through the list. Also, the swipe gesture may cause pushing of the pre-selection indication against a boundary of the display such as in the direction of the swipe gesture such that the item associated with the pre-selection indication remains part of the displayed subset.
Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
The therapeutic outcomes of patients with eosinophilic chronic rhinosinusitis (ECRS) remain unsatisfactory, largely because the underlying mechanisms of eosinophilic inflammation are uncertain. Here, it is shown that the nasal secretions of ECRS patients have high eosinophil extracellular trap (EET) and cell-free DNA (cfDNA) levels. Moreover, the cfDNA induced EET formation by activating toll-like receptor 9 (TLR9) signaling. After demonstrating that DNase I reduced eosinophilic inflammation by modulating EET formation, linear polyglycerol-amine (LPGA)-coated TiS2 nanosheets (TLPGA) as functional 2D nanoplatforms with low cytotoxicity, mild protein adsorption, and increased degradation rate is developed. Due to the more flexible linear architecture, TLPGA exhibited higher cfDNA affinity than the TiS2 nanosheets coated with dendritic polyglycerol-amine (TDPGA). TLPGA reduced cfDNA levels in the nasal secretions of ECRS patients while suppressing cfDNA-induced TLR9 activation and EET formation in vitro. TLPGA displayed exceptional biocompatibility, preferential nasal localization, and potent inflammation modulation in mice with eosinophilic inflammation. These results highlight the pivotal feature of the linear molecular architecture and 2D sheet-like nanostructure in the development of anti-inflammation nanoplatforms, which can be exploited for ECRS treatment.
Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza- like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction [see Adverse Reactions (6.1)]. In Studies 1 and 2 [see Clinical Studies (14)], patients received methylprednisolone (or an equivalent steroid), an antihistamine, and possibly other pre- medication (i.e., acetaminophen) to reduce the risk of infusion reactions prior to each infusion. The incidence of infusion reactions in Studies 1 and 2 in patients who received treatment with BRIUMVI was 48%, with the highest incidence within 24 hours of the first infusion. In Studies 1 and 2, there were no fatal infusion reactions, but 0.6% of patients treated with BRIUMVI experienced infusion reactions that were serious, some requiring hospitalization.

Observe patients treated with BRIUMVI for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions. Post-infusion monitoring of subsequent infusions is at physician discretion unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion.

Reducing the Risk of Infusion Reactions and Managing Infusion Reactions

Administer pre-medication (e.g., methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of infusion reactions [see Dosage and Administration (2.2)]. The addition of an antipyretic (e.g., acetaminophen) may also be considered [see Dosage and Administration (2.2)].

Management recommendations for infusion depend on the type and severity of the reaction. For life-threatening infusion reactions, stop the infusion immediately, permanently discontinue BRIUMVI, and provide appropriate supportive treatment [see Dosage and Administration (2.5)]. For less severe infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.
The present invention relates to a monoclonal anti-human BCMA antibody, or a single chain variable fragment (scFv) comprising a VH having the amino acid sequence shown in SEQ ID No. 6 and a VL having the amino acid sequence shown in SEQ ID No. 7. The invention also relates to a BCMA Chimeric Antigen Receptor (CAR) comprising, from N-terminus to C-terminus: (i) a single chain variable fragment (scFv) of the invention, (ii) a transmembrane domain, (iii) at least one costimulatory domain, and (iv) an activation domain. The monoclonal antibodies of the invention exhibit selective and high affinity binding to BCMA. BCMA CAR-T cells based on the BCMA scFv of the present invention significantly reduce the growth of multiple myeloma tumors in animal models.
Dabigatran is administered in a fixed does without laboratory monitoring and is being compared with warfarin (international normalized ratio, but only hundreds of evidence from Asia events in several multicenter, prospective, randomized trails. It remains unclear that whether Dabigatran is safety in China clinical practice and no need of monitor test. We identified participants as those diagnosed as having nonvalved atrial fibrillation, and who initiated dabigatran after diagnosis.We followed up each individual from the first prescription of dabigatran until discontinued use or switch of anticoagulants, death, or other outcomes or until one year later. We categorized bleeding events as major and minor events according to anatomical position. We defined time to bleeding as days between the first dabigatran prescription and the date of the bleeding event. We analyzed the time to the first bleeding event, as well as the time to the first major hemorrhage, intracranial hemorrhage, gastrointestinal bleeding, hematuria, vaginal bleeding, hemarthrosis, hemoptysis, and epistaxis.
Two sessions of transcranial magnetic stimulation each day for 6 monts. The coil of the device does not emit a magnetic field.
BACKGROUND: The trans femoral ipsilateral approach is often adopted for endovascular treatment (EVT) for better steerability of guidewires or better device deliverability. However, contrary to the trans femoral contralateral approach, ipsilateral antegrade puncture sometimes causes peculiar bleeding complications.
CASE PRESENTATION: A 76-year-old female underwent EVT for chronic occlusion of the left superficial femoral artery (SFA) via the ipsilateral antegrade approach. After guidewire passage, we inflated the drug-coated balloons, but angiography showed blood flow stasis at the mid segment of the SFA. We also ensured prolonged balloon inflation, which resulted in favorable blood flow. While trying to ensure hemostasis, the blood pressure remained decreased, but neither bleeding nor superficial hematoma were observed at the puncture site. After hemostasis was achieved, we removed the surgical drape and noticed a swelling in the mid-portion of the thigh, distant from the puncture point. We then approached the left common femoral artery (CFA) contralaterally. Angiography showed continuous bleeding from a little bit distally to the sheath insertion point that was spreading through an intramuscular space. We stopped the bleeding with balloon tamponade inside the CFA. Angiography after hemostasis demonstrated blood flow stasis at the mid-segment of the SFA, similarly as that seen before. We confirmed compression of the SFA by a large hematoma using both intra- and extra- vascular ultrasound. Therefore, we deployed a self-expandable stent at the compressed SFA position. Finally, we achieved favorable blood flow on angiography.
CONCLUSION: We encountered a case that latent bleeding unrecognized in the surgical field persisted while prolonged inflation of DCB was conducted at just proximal SFA. We could have avoided bailout stenting by noticing the bleeding incident in a timely manner. Prediction and prevention are essential for all kinds of procedural complications in EVT.
The MultiSense® strip is a unique, band aid-sized, clinical signal quality, connected strip for real-time monitoring of cardio-respiratory parameters. The MultiSense® strip measures in real-time, remotely and continuously 11 clinical key-indicators by being attached to the patient thorax: Electrocardiogram (ECG) trace, heart rate, oxygen saturation, respiratory rate and relative respiration depth, pulse transit time, plethysmographic trace, perfusion index, skin temperature, physical activity and body position. Designed to be worn continuously for at least seven days, the patient can keep the patch during his sleep or in the shower.

The aim of this study is to determine the quality of measurements of clinical signs provided by MultiSense® strip in comparison to measurements made with conventional medical devices in the hospital setting, in terms of accuracy, connectivity, generation of artefactual data and stability of data transmission. The study population includes 60 patients undergoing visceral or digestive surgery. Once in the post-operative monitoring room, the MultiSense® strip will be attached on patient's thorax. The monitoring will last 7 days through post-operative monitoring room (continuous comparison with reference monitor), general ward (comparison with spot-check monitoring) and patient's home.
This study will follow the classic "3+3" design and increase the dose according to three dose groups. Each dose group will have 3-6 eligible subjects selected according to the inclusion/exclusion criteria, with a dose of 1.0 × 10\^6, 2.0 × 10\^6, 3.0 × Increase the dose by 10\^6 CAR-T cells/kg.
A reagent useful for determining susceptibility to whooping cough by a skintest technique or for immunizing against whooping cough is prepared by disintegrating, without denaturation of the proteins or other constituents, organisms which cause whooping cough, forming an aqueous extract thereof, separating the agglutinogen from the toxins in the extract by precipitation, and purifying the agglutinogen.  The disintegration may be effected by sonic vibrations as described in U.S.A. Specification 2,230,997 or by a ball mill disintegration of organisms desiccated at a very low temperature.  The toxin may be precipitated from an aqueous extract derived from phase I haemophilus pertussis by adjustment of the pH to 4.5 followed by further precipiation at pH 3.9 and 3.0 or by the addition of 25 per cent of ammonium sulphate.  Alternatively, with some strains of B parapertussis, the agglutinogen itself may be precipitated by adjusting the pH to 4-4.5 provided the solution has been previously dialysed free from salt.  According to an example, phase I, H pertussis from a Bordet-Gengon culture medium were disintegrated by sonic vibrations and centrifuged to remove cellular debris.  The liquid was adjusted to pH 4.5 by hydrochloric acid and the resulting toxin precipitate removed and washed.  The combined washings and filtrate were then brought to pH 3.9 by addition of further hydrochloric acid, the further toxin precipitate being removed and washed.  The pH of the combined washings and filtrate was then brought to pH 3.0 to produce a further toxin precipitate which was treated as before.  The combined washings and filtrate was then adjusted to pH 7.0 by the slow addition of sodium hydroxide with agitation, the slight precipitate at pH 5.4-6.4 being centrifugally removed.  The clear, slightly yellow liquid contained pertussis agglutinogen free from p  toxins.  The agglutinogen was precipitated by the addition of a saturated ammonium sulphate solution, and after washing the solution in water and dialysis, was precipitated by the addition of saturated picric acid solution.
Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 μM, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 μM of SSCrFCES inhibits the LPS-induced secretion of hTNF-α and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml/minute. The LD 90  of SSCrFCES for LPS lethality in mice is achieved at 2 μM. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin-induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials. Further embodied in this application is the use of sushi peptides or sushi recombinant proteins to remove endotoxin from liquids.